I-Mab
Global biotech company developing bispecific antibodies for immuno-oncology.
IMAB | US
Overview
Corporate Details
- ISIN(s):
- US44975P1030
- LEI:
- Country:
- United States of America
- Address:
- SUITE 400, 2440 RESEARCH BLVD, 20850 ROCKVILLE
- Website:
- https://www.i-mabbiopharma.com/
- Sector:
- Manufacturing
Description
I-Mab is a global biotechnology company focused on the discovery, development, and commercialization of innovative biologics for the treatment of cancer. The company's core focus is on immuno-oncology, advancing a pipeline of differentiated therapies. Its portfolio includes several clinical-stage assets with an emphasis on bispecific antibodies. Key candidates in development include givastomig, a Claudin 18.2 x 4-1BB bispecific antibody for gastrointestinal cancers, and ragistomig, a PD-L1 x 4-1BB bispecific antibody for patients with advanced solid tumors, particularly those refractory to checkpoint inhibitors. The pipeline also features uliledlimab, a CD73 antibody.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all I-Mab filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for I-Mab
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for I-Mab via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
